Terminated PHASE1/PHASE2 NCT00316537

Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers

A Multicenter, Randomized Study of the Safety and Preliminary Efficacy of Low-Dose Nicotine Gel (ATG002) in Patients With Plantar Diabetic Foot Ulcers

Sponsor: CoMentis

Conditions Diabetic Foot Ulcers

Interventions ATG002 (study drug)

Updated 5 times since 2017 Last updated: Aug 7, 2007 Started: Oct 31, 2006 Completion: Jul 31, 2007

A PHASE1/PHASE2 clinical study on Diabetic Foot Ulcers, this trial is terminated or withdrawn. The trial is conducted by CoMentis and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CoMentis

Data source: CoMentis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Castro Valley, United States , Chapel Hill, United States , Homewood, United States , Lithonia, United States , Miami, United States , Milwaukee, United States , Owings Mills, United States , Phoenix, United States , San Diego, United States and 3 more locations